(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

The firm is touting its AI-driven foundation model's ability to predict how any patient will respond to any drug, allowing sponsors to fine-tune their trials.

These large-cap stocks are growing their top lines at a higher-than-average pace, but prospective investors should be wary of ...

BUFFALO, NY – Five major research centers in New York have banded together to share resources and a manufacturing facility in ...

Over time, these drugs have also been found to help people lose weight by slowing digestion, reducing hunger, and making ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

If you're looking for the best events happening in Cincinnati, you're at the right place. Find your next concert, ball game, ...

A few years have passed since the height of the COVID-19 pandemic, but but researchers estimate millions of people are still ...

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

Two researchers demonstrate how subtle response-time biomarkers – captured in minutes via digital assessments – can detect Alzheimer's and dementia risk far earlier than traditional methods.